Catherine Vasilakis-Scaramozza, Rebecca Persson, George Kafatos, David Neasham, Katrina Wilcox Hagberg, Susan Jick
{"title":"临床实践研究数据链（CPRD） Aurum母婴链接的验证。","authors":"Catherine Vasilakis-Scaramozza, Rebecca Persson, George Kafatos, David Neasham, Katrina Wilcox Hagberg, Susan Jick","doi":"10.1002/pds.5860","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Assess the validity of the Clinical Practice Research Datalink (CPRD) Aurum Mother-Baby Link (MBL).</p><p><strong>Methods: </strong>We assessed the validity of CPRD Aurum MBL pairs using several strategies. Our study population was based on all available MBL pairs in a 100-practice sample of CPRD Aurum. We sent a questionnaire to the general practitioner of a sample of MBL patients asking if linkage was correct and whether delivery date was correct within 14 days. We also compared MBL delivery date to the matched child's birth date in CPRD Aurum. Finally, in the Hospital Episode Statistics (HES) eligible population, we compared MBL delivery date to birthing parent's HES delivery date.</p><p><strong>Results: </strong>The study population included 124 962 MBL pairs: 124 962 livebirths, 91 218 birthing parents, and 123 562 deliveries. Based on 361 questionnaire responses standardized to the MBL population, 85% (95% CI 74%-96%) of pairs were confirmed as correctly matched, <1% (0.04%-1.4%) were incorrectly matched, and 13% (10%-18%) could not be confirmed. For 71% (61%-82%) of the sample, delivery date was correct within 14 days. Among the entire population of 124 962 MBL pairs, 73% of MBL pairs had MBL delivery date within the baby's birth month recorded in CPRD Aurum. Among 79 834 patients with HES linkage, 94% of 107 080 MBL deliveries in CPRD Aurum were confirmed in HES.</p><p><strong>Conclusions: </strong>Our various assessments of CPRD Aurum MBL found the great majority of pairs were correctly matched and most delivery dates were correct within 14 days. Further refinement of delivery dates may be necessary for some studies.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 2","pages":"e5860"},"PeriodicalIF":2.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Validation of Clinical Practice Research Datalink (CPRD) Aurum Mother-Baby Link.\",\"authors\":\"Catherine Vasilakis-Scaramozza, Rebecca Persson, George Kafatos, David Neasham, Katrina Wilcox Hagberg, Susan Jick\",\"doi\":\"10.1002/pds.5860\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Assess the validity of the Clinical Practice Research Datalink (CPRD) Aurum Mother-Baby Link (MBL).</p><p><strong>Methods: </strong>We assessed the validity of CPRD Aurum MBL pairs using several strategies. Our study population was based on all available MBL pairs in a 100-practice sample of CPRD Aurum. We sent a questionnaire to the general practitioner of a sample of MBL patients asking if linkage was correct and whether delivery date was correct within 14 days. We also compared MBL delivery date to the matched child's birth date in CPRD Aurum. Finally, in the Hospital Episode Statistics (HES) eligible population, we compared MBL delivery date to birthing parent's HES delivery date.</p><p><strong>Results: </strong>The study population included 124 962 MBL pairs: 124 962 livebirths, 91 218 birthing parents, and 123 562 deliveries. Based on 361 questionnaire responses standardized to the MBL population, 85% (95% CI 74%-96%) of pairs were confirmed as correctly matched, <1% (0.04%-1.4%) were incorrectly matched, and 13% (10%-18%) could not be confirmed. For 71% (61%-82%) of the sample, delivery date was correct within 14 days. Among the entire population of 124 962 MBL pairs, 73% of MBL pairs had MBL delivery date within the baby's birth month recorded in CPRD Aurum. Among 79 834 patients with HES linkage, 94% of 107 080 MBL deliveries in CPRD Aurum were confirmed in HES.</p><p><strong>Conclusions: </strong>Our various assessments of CPRD Aurum MBL found the great majority of pairs were correctly matched and most delivery dates were correct within 14 days. Further refinement of delivery dates may be necessary for some studies.</p>\",\"PeriodicalId\":19782,\"journal\":{\"name\":\"Pharmacoepidemiology and Drug Safety\",\"volume\":\"34 2\",\"pages\":\"e5860\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacoepidemiology and Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pds.5860\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.5860","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Validation of Clinical Practice Research Datalink (CPRD) Aurum Mother-Baby Link.
Purpose: Assess the validity of the Clinical Practice Research Datalink (CPRD) Aurum Mother-Baby Link (MBL).
Methods: We assessed the validity of CPRD Aurum MBL pairs using several strategies. Our study population was based on all available MBL pairs in a 100-practice sample of CPRD Aurum. We sent a questionnaire to the general practitioner of a sample of MBL patients asking if linkage was correct and whether delivery date was correct within 14 days. We also compared MBL delivery date to the matched child's birth date in CPRD Aurum. Finally, in the Hospital Episode Statistics (HES) eligible population, we compared MBL delivery date to birthing parent's HES delivery date.
Results: The study population included 124 962 MBL pairs: 124 962 livebirths, 91 218 birthing parents, and 123 562 deliveries. Based on 361 questionnaire responses standardized to the MBL population, 85% (95% CI 74%-96%) of pairs were confirmed as correctly matched, <1% (0.04%-1.4%) were incorrectly matched, and 13% (10%-18%) could not be confirmed. For 71% (61%-82%) of the sample, delivery date was correct within 14 days. Among the entire population of 124 962 MBL pairs, 73% of MBL pairs had MBL delivery date within the baby's birth month recorded in CPRD Aurum. Among 79 834 patients with HES linkage, 94% of 107 080 MBL deliveries in CPRD Aurum were confirmed in HES.
Conclusions: Our various assessments of CPRD Aurum MBL found the great majority of pairs were correctly matched and most delivery dates were correct within 14 days. Further refinement of delivery dates may be necessary for some studies.
期刊介绍：
The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report.
Particular areas of interest include:
design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;
comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;
methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;
assessments of harm versus benefit in drug therapy;
patterns of drug utilization;
relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
